

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

TGF beta-1,2,3 Monoclonal Antibody (1D11.16.8), Functional Grade, eBioscience

RRID:AB_2573124

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 16-9243-85, RRID:AB_2573124)

Antibody Information

URL: http://antibodyregistry.org/AB_2573124

Proper Citation: (Thermo Fisher Scientific Cat# 16-9243-85, RRID:AB_2573124)

Target Antigen: TGF beta-1,2,3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Functional, IHC-P, Neu

Antibody Name: TGF beta-1,2,3 Monoclonal Antibody (1D11.16.8), Functional Grade, eBioscience

Description: This monoclonal targets TGF beta-1,2,3

Target Organism: Human, Rat, Canine, Mouse, Rhesus Monkey, Non-human primate, Hamster

Clone ID: Clone 1D11.16.8

Defining Citation: [PMID:16751069](#), [PMID:8914030](#), [PMID:10028970](#), [PMID:17227914](#), [PMID:2537357](#)

Antibody ID: AB_2573124

Vendor: Thermo Fisher Scientific

Catalog Number: 16-9243-85

Alternative Catalog Numbers: 16-9243

Record Creation Time: 20250719T080534+0000

Record Last Update: 20260225T224525+0000

Ratings and Alerts

No rating or validation information has been found for TGF beta-1,2,3 Monoclonal Antibody (1D11.16.8), Functional Grade, eBioscience.

No alerts have been found for TGF beta-1,2,3 Monoclonal Antibody (1D11.16.8), Functional Grade, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wienke J, et al. (2024) Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. Cancer cell, 42(2), 283.

Zhang K, et al. (2023) Targeting GPR65 alleviates hepatic inflammation and fibrosis by suppressing the JNK and NF- κ B pathways. Military Medical Research, 10(1), 56.

St Paul M, et al. (2021) Coenzyme A fuels T cell anti-tumor immunity. Cell metabolism, 33(12), 2415.

Le BV, et al. (2020) TGF β R-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell reports, 33(1), 108221.